Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i2.20
36 pages

Targeted Delivery of Radiolabeled Imaging and Therapeutic Agents: Bifunctional Radiopharmaceuticals

Hideo Saji
Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan

SINOPSIS

Clinical application of radioactive diagnostic and therapeutic agents constitutes one of the great advances in noninvasive medicine, nuclear medicine. The radioactive agents used in the nuclear medical field are called "radiopharmaceuticals," and are required to exhibit high and specific localization of radioactivity into target tissue. Among radionuclides used in radiopharmaceuticals, radiometals such as 99mTc and 111In have received much attention because of their nuclear physical characteristics and widespread availability. However, since these metallic elements are not constituents of bioactive molecules, they cannot simply replace common constituent atoms in biologically interesting compounds. Thus, demand for biospecific radiopharmaceuticals constitutes a great challenge in rational design of biologically active molecules labeled with metallic radionuclides, and evolves into a generation of bifunctional radiopharmaceuticals. Molecules contain both a biologically active site and a chelating group for binding the metallic radionuclide in which attachment of a chelating group does not affect the inherent biospecificity of the mother compound. This paper describes recent progress in research of macro- and small-molecular bifunctional radiopharmaceuticals for targeted diagnosis and therapy.


Articles with similar content:

Stimuli-Responsive Systems with Diverse Drug Delivery and Biomedical Applications: Recent Updates and Mechanistic Pathways
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 3
Ranjot Kaur, Sumant Saini, Bhupinder Singh, Rajneet Kaur Khurana, Babita Garg
A Review on Potential of Proteins as an Excipient for Developing a Nano-Carrier Delivery System
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 5
Pubali Dhar, Amrita Chakraborty
Challenges in the Use of Carbon Nanotubes for Biomedical Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 2
Neelesh Kumar Mehra, Amit Kumar Jain, Narendra Kumar Jain, Neeraj Lodhi, Vaibhav Dubey, Rakesh Raj, Manoj Nahar, Dinesh Mishra
Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 2
Antonella Accardo, Giancarlo Morelli, Paola Ringhieri
KRIOBLAST: A PROMISING CRYOGENIC PLATFORM FOR KINETIC VITRIFICATION BY HYPERFATST COOLING
Second Thermal and Fluids Engineering Conference, Vol.28, 2017, issue
Igor I. Katkov, Vladimir F. Bolyukh